Asthma And COPD Market Analysis | Coherent Market Insights

1
Coherent Market InsightS

• Market Research and Business Consulting
  Services
• https//www.coherentmarketinsights.com/
• COVID-19 Impact Tracker

2
Asthma COPD Market Analysis (2020-2027)

• Chronic Obstructive Pulmonary Disease (COPD) is
  characterized by a persistent blockage of airflow
  in the lungs, which results in abnormal sputum,
  more than a smokers cough or a chronic cough
  and breathlessness. Symptoms of COPD include,
  cough, breathlessness (shortness of breath) and
  wheezing, sputum, chest infections, weight loss,
  tiredness, and ankle swelling.
• The global asthma and COPD market is estimated to
  account for US 30,710.2 Mn in terms of value
  in 2020 and is expected to reach US 42,608 Mn by
  the end of 2027.

3
Global Asthma and COPD Market Drivers

• Increasing prevalence of COPD is expected to
  propel growth of the global asthma and COPD
  market over the forecast period. For instance,
  according to a report by Global Initiative for
  Chronic Obstruction Diseases 2018 report, COPD
  is expected to result in 4.5 million global
  deaths annually by 2030.
• Moreover, increasing member of smokers is also
  expected to aid in growth of the market. For
  instance, according to the World Health
  Organization, 1.337 billion people smoked tobacco
  worldwide in 2018.
• Combination Therapies held dominant position in
  the global asthma and COPD market in 2019,
  accounting for 57.0 share in terms of value,
  followed by Bronchodilators and
  Anti-Inflammatories, respectively.

4
Figure 1. Global Asthma and COPD Market Share
(), by Value, by Drug Type, 2019
5
Global Asthma and COPD Market Restraints

• High cost of asthma treatment is expected to
  hinder growth of the market. For instance, the
  annual per-person medical cost of asthma is
  around US 4,000 in the U.S.
• Moreover, asthma treatment is a long process and
  patients affected with the disease have to follow
  many precautions. Very often patients discontinue
  the treatment halfway because of high cost. This
  is also expected to limit the market growth.

6
s
7
Figure 2. Global Asthma and COPD Market Value
(US Mn), and Y-o-Y Growth (), 2019-2027
8
Market Trends/Key Takeaways

• Major organizations are focused on offering
  guidelines regarding management of asthma during
  the Covid-19 pandemic. For instance, in July
  2020, Asthma and Allergy Foundation of America
  released a comprehensive guide, the COVID-19 and
  Asthma Toolkit for Schools to help educators and
  families of children living with asthma navigate
  best methods to stay healthy for those returning
  to classrooms during the COVID-19 pandemic.
• RD of novel therapies is expected to propel
  growth of the global asthma and COPD market. For
  instance, the study, Masitinib Significantly
  Decreases the Rate of Asthma Exacerbations in
  Patients with Severe Asthma Uncontrolled by Oral
  Corticosteroids A Phase 3 Multicenter Study,
  reported in June 2020, stated that Masitinib
  significantly reduced asthma exacerbations in
  patients with severe asthma uncontrolled by oral
  corticosteroids compared with placebo treatment.

9
Global Asthma and COPD Market Competitive
Landscape

• Major players operating in the global asthma and
  COPD market include, AstraZeneca, Novartis AG,
  GlaxoSmithKline plc, Merck Co., Verona Pharma
  plc,, Regeneron Pharmaceuticals, Inc.,
  GlaxoSmithKline plc, and Boehringer Ingelheim
  GmbH.

10
Global Asthma and COPD Market Key Developments

• Major players in the market are focused on RD of
  new therapies to expand their product portfolio.
  For instance, in July 2020, AstraZeneca's results
  from the positive Phase III ETHOS trial were
  published in the New England Journal of Medicine.
  The study demonstrated that the
  triple-combination therapy PT010
  (budesonide/glycopyrronium/formoterol fumarate)
  reduced the rate of moderate or severe
  exacerbations compared with two dual-combination
  therapies in patients with moderate to very
  severe COPD.
• Major players in the market are also focused on
  approval and launch of new products to expand
  their product portfolio. For instance, in
  February 2020, European Medicines Agency accepted
  GlaxoSmithKline plcs regulatory submission
  seeking an additional indication for the use of
  once-daily, single-inhaler triple therapy,
  Trelegy Ellipta (fluticasone furoate/umeclidinium/
  vilanterol or FF/UMEC/VI) for the treatment of
  asthma in adults.

11

• Request sample copy here
• Request PDF brochure here
• Request Customization here
• Talk to Analyst
• Buy Now
• Reference
• https//www.coherentmarketinsights.com/market-insi
  ght/asthma-and-copd-market-4002

12
About Us

• Coherent Market Insights is a global market
  intelligence and consulting organization focused
  on assisting our plethora of clients achieve
  transformational growth by helping them make
  critical business decisions.
• What we provide
• Customized Market Research Services
• Industry Analysis Services
• Business Consulting Services
• Market Intelligence Services
• Long term Engagement Model
• Country Specific Analysis

13
Contact Us   

• Mr. Shah
• Coherent Market Insights Pvt. Ltd.
• Address 1001 4th ave, 3200 Seattle, WA 98154,
  U.S.
• Phone [phone]
• Email sales_at_coherentmarketinsights.com

14
Thank You!

• Kindly follow CMI Social Media Profiles for the
  latest company updates
• Facebook
• Linkedin
• Twitter
• https//www.coherentmarketinsights.com/